Cardiac Science Inc. and Quinton Cardiology Systems Inc. finalized their combination on Thursday.
Shareholders of Irvine-based Cardiac Science and Bothell, Wash.-based Quinton had approved the deal Wednesday.
The combined company, which is based out of Bothell, a Seattle suburb, is called Cardiac Science Corp.
Cardiac and Quinton first announced their plans to combine in February.
“We believe the new company will have enhanced prospects for revenue growth based on our expanded product portfolio, stronger distribution capabilities in both the domestic and international markets, and the potential to leverage combined technological expertise and manufacturing strengths,” said John R. Hinson, Quinton’s former chief executive who is taking the CEO role at the new company.
Quinton made heart-related devices such as monitors. Cardiac Science produced defibrillators that are used in emergencies to treat heart attacks.
Raymond W. Cohen, former chief executive of Cardiac Science in Irvine, is chairman of the combined company.
Shares of Cardiac Science started trading Thursday on Nasdaq under the “CSCX” symbol. They were at $11. in trading Thursday.
Quinton shareholders received about 0.8 shares of a new Cardiac Science share, with former Cardiac Science shareholders receiving 0.1 share of the combined company’s stock.
